Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

From cyclosporine to the future.

C Ponticelli1, A Tarantino, M Campise

  • 1Division of Nephrology, Ospedale Maggiore IRCCS, Milano, Italy. Ponticelli@policlinico.mi.it

Transplantation Proceedings
|March 26, 2004
PubMed
Summary

Cyclosporine (CsA) demonstrates improved long-term graft survival in kidney transplant patients compared to azathioprine. Monotherapy with CsA reduces side effects, while basiliximab addition lowers acute rejection rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idiopathic erythrocytosis: a germline disease?

Clinical and experimental medicine·2024
Same author

Reply to the letter sent by Ceballos-Laitaa et al.

Complementary therapies in clinical practice·2023
Same author

The possible role of glutathione-S-transferase activity in diabetic nephropathy.

International journal of immunopathology and pharmacology·2015
Same author

Fat saturation technique and gadolinium in MRI of lumbar spinal degenerative disease.

The neuroradiology journal·2013
Same author

Vasospasm and cerebral infarction from pituitary apoplexy. A case report.

The neuroradiology journal·2013
Same author

Cortical activity and connectivity of human brain during the prisoner's dilemma: an EEG hyperscanning study.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2007

Area of Science:

  • Nephrology
  • Immunosuppression
  • Transplantation

Background:

  • Cyclosporine (CsA) is a cornerstone of immunosuppression in renal transplantation.
  • Extensive clinical trials have evaluated various CsA-based regimens.
  • Long-term outcomes and side effect profiles remain critical considerations.

Purpose of the Study:

  • To review cumulative experience with CsA in renal transplantation.
  • To assess the efficacy and safety of different CsA-based immunosuppressive strategies.
  • To identify current challenges and future directions in immunosuppression.

Main Methods:

  • Analysis of data from multiple randomized controlled trials and multicenter studies.
  • Review of cumulative patient experience and graft survival data.

Related Experiment Videos

  • Inclusion of ongoing trials investigating novel immunosuppressive agents.

    • Main Results:

    • CsA-treated patients showed better 10-year graft survival than azathioprine.
    • CsA monotherapy and double/triple therapy demonstrated similar long-term graft survival, with monotherapy having fewer steroid side effects.
    • Addition of basiliximab to triple therapy reduced acute rejection without increasing side effects.
    • Mean graft half-life was 18.7 years for cadaver and 31.9 years for living donors.
    • No significant graft function decline observed in grafts functioning at 15 years.

    Conclusions:

    • CsA-based immunosuppression offers favorable long-term graft survival in renal transplantation.
    • Minimizing steroid use through monotherapy or alternative agents is beneficial.
    • Ongoing research focuses on addressing calcineurin inhibitor nephrotoxicity and steroid-related cardiovascular risks with newer agents.